Annual Total Liabilities
$2.71 M
-$1.31 M-32.54%
01 December 2023
Summary:
COSCIENS Biopharma annual total liabilities is currently $2.71 million, with the most recent change of -$1.31 million (-32.54%) on 01 December 2023. During the last 3 years, it has fallen by -$1.15 million (-29.76%).CSCI Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Liabilities
$23.75 M
-$63.00 K-0.26%
01 September 2024
Summary:
COSCIENS Biopharma quarterly total liabilities is currently $23.75 million, with the most recent change of -$63.00 thousand (-0.26%) on 01 September 2024. Over the past year, it has increased by +$20.83 million (+711.14%).CSCI Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CSCI Total Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -32.5% | +711.1% |
| 3 y3 years | -29.8% | +535.0% |
| 5 y5 years | +74.8% | +486.9% |
CSCI Total Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | ||||
| 5 y | 5 years | ||||
| alltime | all time | -65.0% | -0.3% |
COSCIENS Biopharma Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $23.75 M(-0.3%) |
| June 2024 | - | $23.82 M(+839.6%) |
| Mar 2024 | - | $2.54 M(-6.3%) |
| Dec 2023 | $2.71 M(-32.5%) | $2.71 M(-7.6%) |
| Sept 2023 | - | $2.93 M(+9.7%) |
| June 2023 | - | $2.67 M(-21.6%) |
| Mar 2023 | - | $3.41 M(-15.1%) |
| Dec 2022 | $4.01 M(+53.6%) | $4.01 M(+39.9%) |
| Sept 2022 | - | $2.87 M(-3.1%) |
| June 2022 | - | $2.96 M(+11.5%) |
| Mar 2022 | - | $2.65 M(+1.6%) |
| Dec 2021 | $2.61 M(-32.2%) | $2.61 M(-30.2%) |
| Sept 2021 | - | $3.74 M(+0.9%) |
| June 2021 | - | $3.71 M(+2.3%) |
| Mar 2021 | - | $3.63 M(-5.9%) |
| Dec 2020 | $3.85 M(+1.5%) | $3.85 M(+19.3%) |
| Sept 2020 | - | $3.23 M(+2.7%) |
| June 2020 | - | $3.14 M(+1.6%) |
| Mar 2020 | - | $3.09 M(-18.5%) |
| Dec 2019 | $3.79 M(+145.0%) | $3.79 M(-6.2%) |
| Sept 2019 | - | $4.05 M(+2.7%) |
| June 2019 | - | $3.94 M(-1.3%) |
| Mar 2019 | - | $3.99 M(+157.8%) |
| Dec 2018 | $1.55 M(-63.0%) | $1.55 M(-31.3%) |
| Sept 2018 | - | $2.26 M(-41.5%) |
| June 2018 | - | $3.86 M(+2.5%) |
| Mar 2018 | - | $3.76 M(-10.1%) |
| Dec 2017 | $4.19 M(+41.0%) | $4.19 M(+58.0%) |
| Sept 2017 | - | $2.65 M(+2.8%) |
| June 2017 | - | $2.58 M(-4.9%) |
| Mar 2017 | - | $2.71 M(-8.7%) |
| Dec 2016 | $2.97 M(-47.4%) | $2.97 M(-24.1%) |
| Sept 2016 | - | $3.91 M(-21.8%) |
| June 2016 | - | $5.00 M(-12.7%) |
| Mar 2016 | - | $5.73 M(+1.6%) |
| Dec 2015 | $5.64 M(+17.1%) | $5.64 M(+12.9%) |
| Sept 2015 | - | $5.00 M(-4.3%) |
| June 2015 | - | $5.22 M(+9.9%) |
| Mar 2015 | - | $4.75 M(-1.3%) |
| Dec 2014 | $4.82 M(+5.7%) | $4.82 M(+3.1%) |
| Sept 2014 | - | $4.67 M(-15.9%) |
| June 2014 | - | $5.56 M(+16.8%) |
| Mar 2014 | - | $4.76 M(+4.3%) |
| Dec 2013 | $4.56 M(+17.1%) | $4.56 M(+61.9%) |
| Sept 2013 | - | $2.81 M(-8.9%) |
| June 2013 | - | $3.09 M(-0.8%) |
| Mar 2013 | - | $3.11 M(-20.0%) |
| Dec 2012 | $3.89 M(+8.8%) | $3.89 M(-0.3%) |
| Sept 2012 | - | $3.90 M(+18.5%) |
| June 2012 | - | $3.30 M(-12.1%) |
| Mar 2012 | - | $3.75 M(+4.9%) |
| Dec 2011 | $3.58 M(+3.0%) | $3.58 M(+12.4%) |
| Sept 2011 | - | $3.18 M(-5.0%) |
| June 2011 | - | $3.35 M(-4.0%) |
| Mar 2011 | - | $3.49 M(+0.5%) |
| Dec 2010 | $3.47 M | $3.47 M(-0.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2010 | - | $3.50 M(-3.6%) |
| June 2010 | - | $3.63 M(-12.5%) |
| Mar 2010 | - | $4.15 M(+4.8%) |
| Dec 2009 | $3.96 M(-7.7%) | $3.96 M(+3.4%) |
| Sept 2009 | - | $3.83 M(+6.5%) |
| June 2009 | - | $3.59 M(-9.9%) |
| Mar 2009 | - | $3.99 M(-7.0%) |
| Dec 2008 | $4.29 M(+40.0%) | $4.29 M(+15.3%) |
| Sept 2008 | - | $3.72 M(-0.9%) |
| June 2008 | - | $3.75 M(+20.3%) |
| Mar 2008 | - | $3.12 M(+1.8%) |
| Dec 2007 | $3.06 M(+103.0%) | $3.06 M(+26.4%) |
| Sept 2007 | - | $2.42 M(-8.9%) |
| June 2007 | - | $2.66 M(+48.4%) |
| Mar 2007 | - | $1.79 M(+18.8%) |
| Dec 2006 | $1.51 M(-10.5%) | $1.51 M(+1.5%) |
| Sept 2006 | - | $1.49 M(-21.9%) |
| June 2006 | - | $1.90 M(+5.0%) |
| Mar 2006 | - | $1.81 M(+7.6%) |
| Dec 2005 | $1.69 M(+26.3%) | $1.69 M(+58.9%) |
| Sept 2005 | - | $1.06 M(-16.2%) |
| June 2005 | - | $1.27 M(-9.3%) |
| Mar 2005 | - | $1.39 M(+4.5%) |
| Dec 2004 | $1.33 M(+98.1%) | $1.33 M(+51.2%) |
| Sept 2004 | - | $882.30 K(+5.8%) |
| June 2004 | - | $834.30 K(+49.7%) |
| Mar 2004 | - | $557.20 K(-17.2%) |
| Dec 2003 | $673.30 K(-18.4%) | $673.30 K(+7.3%) |
| Sept 2003 | - | $627.70 K(-24.2%) |
| June 2003 | - | $828.60 K(-12.1%) |
| Mar 2003 | - | $942.20 K(+14.2%) |
| Dec 2002 | $824.70 K(-13.1%) | $824.70 K(-2.9%) |
| Sept 2002 | - | $849.30 K(-20.1%) |
| June 2002 | - | $1.06 M(+12.3%) |
| Mar 2002 | - | $946.90 K(-0.2%) |
| Dec 2001 | $948.90 K(-47.0%) | $948.90 K(-6.7%) |
| Sept 2001 | - | $1.02 M(-19.9%) |
| June 2001 | - | $1.27 M(-25.2%) |
| Mar 2001 | - | $1.70 M(-5.2%) |
| Dec 2000 | $1.79 M(+18.4%) | $1.79 M(-4.4%) |
| Sept 2000 | - | $1.87 M(+2.8%) |
| June 2000 | - | $1.82 M(+5.9%) |
| Mar 2000 | - | $1.72 M(+13.8%) |
| Dec 1999 | $1.51 M(+45.5%) | $1.51 M(+16.9%) |
| Sept 1999 | - | $1.29 M(+12.2%) |
| June 1999 | - | $1.15 M(-3.3%) |
| Mar 1999 | - | $1.19 M(+14.7%) |
| Dec 1998 | $1.04 M(-59.8%) | $1.04 M(-11.8%) |
| Sept 1998 | - | $1.18 M(-57.7%) |
| June 1998 | - | $2.79 M(+4.3%) |
| Mar 1998 | - | $2.68 M(+3.5%) |
| Dec 1997 | $2.59 M(-66.6%) | $2.59 M(-70.7%) |
| Sept 1997 | - | $8.83 M(+15.0%) |
| June 1997 | - | $7.68 M(+4.9%) |
| Mar 1997 | - | $7.32 M |
| Dec 1996 | $7.74 M | - |
FAQ
- What is COSCIENS Biopharma annual total liabilities?
- What is the all time high annual total liabilities for COSCIENS Biopharma?
- What is COSCIENS Biopharma annual total liabilities year-on-year change?
- What is COSCIENS Biopharma quarterly total liabilities?
- What is the all time high quarterly total liabilities for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly total liabilities year-on-year change?
What is COSCIENS Biopharma annual total liabilities?
The current annual total liabilities of CSCI is $2.71 M
What is the all time high annual total liabilities for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual total liabilities is $7.74 M
What is COSCIENS Biopharma annual total liabilities year-on-year change?
Over the past year, CSCI annual total liabilities has changed by -$1.31 M (-32.54%)
What is COSCIENS Biopharma quarterly total liabilities?
The current quarterly total liabilities of CSCI is $23.75 M
What is the all time high quarterly total liabilities for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly total liabilities is $23.82 M
What is COSCIENS Biopharma quarterly total liabilities year-on-year change?
Over the past year, CSCI quarterly total liabilities has changed by +$20.83 M (+711.14%)